Cell-Surface Central Nervous System Autoantibodies: Clinical Relevance and Emerging Paradigms

Sarosh R. Irani, DPhil,1,2 Jeffrey M. Gelfand, MD,2 Adam Al-Diwani, MD,1 and Angela Vincent, FRCPATH1

The recent discovery of several potentially pathogenic autoantibodies has helped identify patients with clinically distinctive central nervous system diseases that appear to benefit from immunotherapy. The associated autoantibodies are directed against the extracellular domains of cell-surface–expressed neuronal or glial proteins such as LGI1, N-methyl-D-aspartate receptor, and aquaporin-4. The original descriptions of the associated clinical syndromes were phenotypically well circumscribed. However, as availability of antibody testing has increased, the range of associated patient phenotypes and demographics has expanded. This in turn has led to the recognition of more immunotherapy-responsive syndromes in patients presenting with cognitive and behavioral problems, seizures, movement disorders, psychiatric features, and demyelinating disease. Although antibody detection remains diagnostically important, clinical recognition of these distinctive syndromes should ensure early and appropriate immunotherapy administration. We review the emerging paradigm of cell-surface–directed antibody–mediated neurological diseases, describe how the associated disease spectrums have broadened since the original descriptions, discuss some of the methodological issues regarding techniques for antibody detection and emphasize considerations surrounding immunotherapy administration. As these disorders continue to reach mainstream neurology and even psychiatry, more cell-surface–directed antibodies will be discovered, and their possible relevance to other more common disease presentations should become more clearly defined.

Ann Neurol 2014;76:168–184
| Antibody   | Frequent clinical associations                                                                 | Tumor/ infectious associations                                                                 | Expanding phenotypic spectrum                                                                 |
|------------|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|
| NMDAR      | Diffuse encephalitis with psychiatric features, cognitive impairment, seizures, movement disorder, dysautonomia, and reduction in consciousness | Ovarian teratoma in about 30%<sup>5,46</sup>; Relapses post-HSV encephalitis with NMDAR antibodies<sup>75–78</sup> | Few cases with purely psychotic features<sup>38,53,160</sup>; predominant movement disorder<sup>161</sup>; few with predominant cryptogenic epilepsy syndrome<sup>162</sup> |
| LGI1       | LE with faciobrachial dystonic seizures and serum hyponatremia                                 | <10% (various tumors described)<sup>29,30,68,69</sup>                                         | Cryptogenic epilepsies<sup>60,62</sup>                                                                        |
| CASPR2     | Morvan syndrome with psychiatric features, insomnia, dysautonomia, and neuromyotonia (often with LGI1 antibodies); less frequently LE | Thymoma (~30%)<sup>20,157</sup>                                                               | Cryptogenic epilepsies<sup>60,62</sup>; Guillain-Barre-like syndrome<sup>163</sup>                     |
| AMPAR      | LE                                                                                              | Lung, breast, thymoma (~50%)<sup>41,55</sup>                                                  | Atypical psychosis<sup>55</sup>                                                                               |
| GlyR       | PERM but also some SPS and related syndromes                                                    | Thymoma rarely (<10%)<sup>18,89,158</sup>                                                     | LE, brainstem encephalitis<sup>124</sup>; cryptogenic epilepsies<sup>60,164</sup>                    |
| GABA<sub>B</sub> | LE                                                                              | Lung (~50%)<sup>62</sup>                                                                    | Encephalopathy<sup>165</sup>                                                                              |
| AQP4       | NMOSD                                                                             | Rare<sup>159</sup>; relapses often precipitated by various infections<sup>131</sup>            | Encephalopathy, including pediatric ADEM<sup>166</sup>                                                   |
| MOG        | NMOSD                                                                             | None yet known                                                                               |                                                                                                             |
| NMDAR | LGI1 | CASPR2 | AMPAR | GlyR | GABA<sub>B</sub> | AQP4 | MOG |
|-------|------|--------|-------|------|-----------------|------|-----|
| Approximate number of reported cases since first description | 700 in 6 years | 250 in 3 years | 30 in 3 years | 25 in 4 years | 60 in 5 years | 30 in 3 years | >2,000 in 8 years | ~30 in 1 year |
| Prevalence in clinically defined tested cohorts | 9/48 (19%) with unknown encephalitis | 6/62 (10%) with unknown encephalitis | 24/27 (89%) with Morvan syndrome | 15/410 (4%) with suspected autoimmune encephalitis | Mainly seen in PERM<sup>21,89,91,158</sup>; 10/81 (12%) with SPS<sup>18</sup>; 1/48 (2%) pediatric encephalopathies | 10/70 (14%) of LE cases | 70–80% of patients with NMOSD<sup>100,110</sup> | 16/215 (7%) NMOSD<sup>110</sup> |
| Prevalence (%) in healthy/disease cohorts | 0–1.2/0–1.3 | 0–0.06/0–0.04<sup>2,33</sup> | 0–0.29/0–0.32 | 0–0.23/0–0.04<sup>41</sup> | 0.06–1.2/0.12<sup>18</sup> | 0/0–0.04<sup>42</sup> | 0/0–0.04<sup>100</sup> | 0–0.06/0.08–2<sup>112</sup> |
| Primary cell type/antigenic target | Neuron/NR1 subunit | Neuron | Neuron | Neuron/GluR1/2 receptor | Neuron/ζ1 subunit | Astrocyte/M23 arrays | Oligodendrocyte |

For neuronal- or glial-surface–directed antibodies reported in >20 cases and in >1 publication. LE produces amnesia, confusion, and seizures (additional features noted above within each antibody specificity).

*Data are from Dahm et al.<sup>136</sup> plus other papers as referenced within the table.

ADEM = acute disseminated encephalomyelitis; AMPAR = α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor; AQP4 = aquaporin-4; CASPR2 = contactin-associated protein 2; GABA<sub>B</sub> = γ-aminobutyric acidB; GlyR = glycine receptor; HSV = herpes simplex virus; LE = limbic encephalitis; LGI1 = leucine-rich glioma-inactivated 1; MOG = myelin oligodendrocyte glycoprotein; NMDAR = N-methyl-D-aspartate receptor; NMOSD = neuromyelitis optica spectrum disorder; PERM = progressive encephalomyelitis with rigidity and myoclonus; SPS = stiff-person syndrome.
the N-methyl-D-aspartate receptor (NMDAR) and components of the voltage-gated potassium channel (VGKC) complex (see Figs 1F and 2A), which includes leucine-rich glioma-inactivated 1 (LG11), contactin-associated protein 2 (CASPR2), and contactin-2. In the United Kingdom, NMDAR, aquaporin-4 (AQP4) and LG11 antibodies occur at a rate of approximately 2 new cases per million persons per year.12,13

Glutamic acid decarboxylase (GAD) antibodies lie in a hinterland between classical paraneoplastic and...
FIGURE 2: (A) The phenotype spread of voltage-gated potassium channel (VGKC) complex, leucine-rich glioma-inactivated 1 (LGI1), and contactin-associated protein 2 (CASPR2) antibodies. The relative proportions of patients with LGI1 and CASPR2 antibodies and those who remain without a known cell-surface antigenic target (Neuoglial cell-surface antibody [NGSAb] unknown) are depicted in the gradient bars. Movement disorders include ataxia, chorea, and parkinsonism. A number of patients, especially those with cramp fasciculation syndrome–neuromyotonia (CFS-NMT; high frequency discharges shown) and epilepsy (excluding faciobrachial dystonic seizures [FBDS]) currently have no defined antigenic target (NGSAb unknown), although their sera precipitate VGKC complexes in the radioimmunoassay. (B) High levels of glutamic acid decarboxylase (GAD) antibodies are associated with a variety of syndromes, including cerebellar ataxia, stiff-person syndrome (SPS), variant SPS (vSPS), progressive encephalomyelitis with rigidity and myoclonus (PERM), limbic encephalitis (LE), and epilepsy. Glycine-alpha1 receptor antibodies have been reported in patients with PERM, vSPS, and SPS in order of decreasing frequency; dipeptidyl peptidase IV–related protein (DPPX) antibodies in some patients with vSPS/PERM; and antibodies against γ-aminobutyric acid_b receptor (GABA_bR) and z-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor (AMPAR) in some patients with GAD antibodies and LE but not to date in cases with epilepsy alone. Their relative frequencies, and those of the NGSAb unknown patients, are depicted in the gradient bars, where a darker color implies a higher chance of finding that antibody.
NGSAb (see Fig 2B). GAD is an intracellular enzyme, GAD-antibody titers do not usually correlate with clinical outcomes, and yet GAD-antibody–associated syndromes (see Fig 2B) are infrequently seen with tumors.14,15 Furthermore, despite GAD’s intracellular localization, some articles do highlight the pathogenic potential of GAD antibodies.16 Interestingly, there are recent reports of NGSAbs coexisting with GAD antibodies.17–19 and the coexistence of >1 potentially relevant NGSAb, or 1 NGSAb and 1 intracellularly directed antibody, is increasingly recognized.20–22

Many previous reviews2,3,7,10,23 have used the autoantibody specificity to categorize associated syndromes (see Table 1). Here, we also outline the clinical features that should alert neurologists to the possibility of a NGSAb (Table 2) and may assist in treating the patient before antibody results are available. One consequence of the increasing availability and commercial accessibility of NGSAb testing is the recognition of patients with “positive” antibodies that do not fit established disease phenotypes or are discovered in nonclassical clinical scenarios. Therefore, we also discuss the relative merits of antibody-detection methods and the diversification of recognized phenotypes or “phenotype spread” in NGSAb-associated syndromes (examples in Fig 2).

Finally, we review the rationale and evidence for immunosuppressive therapy in these conditions.

Red Flags to the Presence of a Cell-Surface CNS-Directed Autoantibody When Seeing Patients With...

Cognitive Impairment: Encephalitis, Encephalopathy, and Dementia

The onset of amnesia, disorientation, and personality change over days or a few weeks should prompt consideration of a rapidly progressive dementia (see Table 2).24 Antibody-associated conditions should be considered high within this differential diagnosis, particularly VGKC-complex antibodies in middle-aged and elderly patients (see Table 1).25–28

VGKC-complex antibody–associated encephalopathy/limbic encephalitis (LE) was first described in 2 patients in 200129 and in 2 series in 2004.30,31 It subsequently became clear that these antibodies, measured by radioimmunoprecipitation from solubilized mammalian brain membranes, were directed against the extracellular domains of neuronal proteins that are tightly complexed with VGKCs in situ (see Fig 1F).32 In patients with LE, the commonest target is LGI1 (in 80–90%),32,33,34 in 5 to 10% of cases the target is CASPR2, very few have contactin-2 antibodies, and some patients have no defined target.32 Seizures are present in the majority of LGI1-antibody–positive cases, and serum hyponatremia is seen in about 60%.30–33 These 2 features—seizures and hyponatremia—coupled with a subacute onset, provide a strong indicator of an immunotherapy-responsive disease, distinct from other rapidly progressive dementias such as Creutzfeldt–Jakob disease (CJD).34 However, routine cerebrospinal fluid (CSF) analysis and brain magnetic resonance imaging (MRI) are normal in around 75% and 50% of cases with VGKC-complex antibodies respectively,30–33 so the key to confirming this diagnosis is antibody testing. Various epilepsies, movement disorders (discussed below), and neuromyotonia are also recognized in patients with VGKC-complex antibodies. Over time, the spread in the demographic associated with VGKC-complex antibodies has meant females are now recognized as often as males, and the associated tumor frequency appears to be decreasing (Fig 3A). Some recent reports have noted children with cognitive impairment, seizures, and VGKC-complex antibodies, although they lack the distinctive LGI1 or CASPR2 antibodies, hyponatremia, or faciobrachial dystonic seizures (FBDS; see below) often seen in adults (see Fig 3C).35–39

Other NGSAbs have been identified in a small number of patients with typical limbic encephalopathies (see Table 1); γ-aminobutyric acid receptor (GABAγR) and α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor (AMPA) antibodies have been described mostly in association with tumors,40–42 including small-cell lung, thymoma, and breast. Importantly, even in these patients with NGSAbs and paraneoplastic disease, the syndromes appear to be treatment-responsive, emphasizing the pathogenic importance of NGSAbs.

Psychiatric Features

Patients with VGKC-complex and GAD antibodies may present with psychiatric features, including delusions, hallucinations, depression, mania, and prominent emotionality, but usually these are overwhelmed by amnesia, disorientation, and executive dysfunction.15,32,43,44 By contrast, patients with NMDAR antibodies typically show a diffuse encephalitis with prominent and early psychiatric features,45,46 which may be the first and only recognized feature of the disease.47,48

NMDAR antibodies were first described in young women with ovarian teratomas, who typically developed encephalitis with CSF pleocytosis and abnormal magnetic resonance brain imaging.49 Since this description, the phenotype spread of NMDAR antibodies has evolved so that NMDAR-antibody encephalitis is now predominantly a disease of children and young adults without a tumor (see Fig 3B), usually with a normal brain MRI.46,50,51 After a brief prodrome, with fever and...
## TABLE 2. Features That Should Raise Suspicion of Neuronal-Surface–Directed Antibodies in Patients Presenting with Cognitive Impairment, Psychiatric Features, Epilepsy, Movement Disorders, or Demyelinating Disease

| Clinical Syndrome | Cognitive Impairment | Psychiatric | Epilepsy | Movement Disorders | Demyelinating Disease |
|-------------------|----------------------|-------------|----------|-------------------|-----------------------|
| **Onset**         | Rapid                | Rapid without a Prodrome of Social Withdrawal | Rapid, Especially When No Prior Seizure History | Rapid | Acute Relapses |
| **Clinical Features** | Memory as a conspicuously affected cognitive domain; often associated seizures including FBDS and hyponatremia (with VGKCc/LGI1-antibodies); underlying cancer possible (GABA\_BR/AMPAR) | First lifetime episode of psychosis; associated seizure(s) and movement disorder (NMDAR/AMPAR); neuromyotonia, dysautonomia, and insomnia (Morvan: CASPR2 > LGI1) | Frequent, localization-related seizures; associated cognitive/psychiatric features in young females (often NMDAR/GAD) or middle-age (VGKCc/LGI1) | Variable phenomenologies including chorea, dystonia, and stereotypies; associated neuropsychiatric features such as anxiety, OCD, or depression (NMDAR/D2R); ataxia (CASPR2, GAD, mGluR1/5); preceding streptococcal infection; hyperekplexia and rigidity (glycine, DPPX) | LETM, severe/bilateral ON, intractable nausea with medullary lesion, drug-refractory pain, often with poor spontaneous recovery (AQP4) or overall better prognosis (MOG) |
| **MRI and CSF (protein, cells, oligoclonal bands) findings** | T2/FLAIR hyperintensity on brain MRI, particularly in medial temporal lobes; normal CSF usually | Various subcortical or cortical T2/FLAIR changes; some appearances suggestive of demyelination; CSF pleocytosis and oligoclonal bands | T2/FLAIR hyperintensity on brain MRI, particularly in medial temporal lobes; normal CSF usually | Usually normal, sometimes medial temporal lobe hyperintensities; often normal CSF | White matter lesions can look very similar to MS; brain may be normal; longitudinally extensive myelitis; CSF typically shows pleocytosis without bands |
| **Associated cell-surface–directed antibodies** | VGKCc (LGI1, CASPR2), AMPAR, GABA\_BR, GAD, DPPX | NMDAR; LGI1 and CASPR2; D2R; AMPAR | VGKCc (especially LGI1), GAD, NMDAR | NMDAR, glycine, VGKCc, GAD, DPPX, D2R | AQP4, MOG |

*One feature common to many of these presentations is the rapid onset, often within days to a few weeks. Routine CSF examination is normal in many cases, especially VGKC-complex antibodies, with variable presence of oligoclonal bands and raised immunoglobulin G index.

**AMPAR = \( \alpha \)-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor; AQP4 = aquaporin-4; CASPR2 = contactin-associated protein 2; CSF = cerebrospinal fluid; D2R = dopamine receptor D2; DPPX = dipeptidyl peptidase IV–related protein; FBDS = faciobrachial dystonic seizures; FLAIR = fluid-attenuated inversion recovery; GABA\_BR = \( \gamma \)-aminobutyric acid \( \beta \) receptor; GAD = glutamic acid decarboxylase; LETM = longitudinally extensive transverse myelitis; LGI1 = leucine-rich glioma-inactivated 1; mGluR = metabotropic glutamategic receptor; MOG = myelin oligodendrocyte glycoprotein; MRI = magnetic resonance imaging; MS = multiple sclerosis; NMDAR = N-methyl-D-aspartate receptor; OCD = obsessive-compulsive disorder; ON = optic neuritis; VGKCc = voltage-gated potassium channel complex.*
headache, the disease often evolves in 2 major stages: an early stage involving seizures and cognitive/psychiatric features, followed 10 to 20 days later by a movement disorder, dysautonomia, and a reduction in consciousness.46 Phenotype spread of NMDAR antibodies has led to the recognition of isolated psychiatric presentations.47,48,52,53 This has fueled renewed interest in the possibility of an autoimmune basis for some forms of schizophrenia. Prominent psychotic features are found in patients with many other NGSAbs including Morvan syndrome (see Fig 2A; see below),20 and basal ganglia encephalitis.54 Furthermore, atypical psychosis has been reported in patients with AMPAR antibodies.55 Patients with these illnesses often show sleep disturbances and movement disorders in conjunction with psychiatric features.20,54 Further studies are now required to understand the relevance of NGSAbs to the assessment and treatment of new onset psychosis.

Given that antigenic targets other than LGI1 and NMDAR are detected relatively infrequently in cognitive
or psychiatric presentations (see Tables 1 and 2). It may be that these 2 most common antibody targets represent the base, rather than the tip, of the rapidly progressive dementia iceberg.

**Epilepsy**

Many patients with adult onset focal epilepsies prove to be a diagnostic and therapeutic challenge. Around 40% do not show responsible imaging abnormalities ("cryptogenic"), and 25% are antiepileptic drug (AED)-refractory. Several studies have confirmed the presence of VGKC-complex antibodies (mainly low levels, <400pM, usually without LGI1 or CASPR2 reactivity) and GAD antibodies (often high levels) in around 10% of adults with longstanding seizures.

More importantly, a small percentage of patients with cryptogenic epilepsies, often with frequent seizures and subtle neuropsychiatric features, have LGI1 (and occasionally CASPR2) antibodies at the onset of their disease, and exhibit a favorable response to immunotherapies (see Table 2). NGSAbs may also be relevant to the etiology of other forms of epilepsy; for example, LE may precede adult onset temporal lobe epilepsy with mesial temporal sclerosis by several years in up to 25% of patients. Therefore, NGSAbs appear to have pathogenic potential in some forms of adult onset epilepsies.

Another example of phenotype spread is the recent observation of a newly described epilepsy termed FBDS. FBDS are the clearest example of a clinically distinctive seizure semiology that appears almost pathognomonic for the presence of the cell-surface–directed LGI1 antibodies. FBDS are adult onset, brief (often <2 seconds), frequent (median 50 per day) events usually involving dystonic posturing of the arm and ipsilateral face grimacing. With increased recognition, this phenotype has spread to include examples of simultaneously bilateral posturing, events of up to 30 seconds in duration, some superimposed clonic movements, and an age range from 28 to 92 years.

Importantly, FBDS occur before the onset of cognitive impairment in around 70% of cases, and they often show a striking preferential response to corticosteroids over AEDs. Their recognition gains further significance given that cognitive impairment might be prevented if FBDS are effectively treated early in the disease course. Similarly, ictal bradycardia preceding cognitive impairment in patients with VGKC-complex/LGI1 antibodies may be a conserved phenotype that permits earlier diagnosis and immunosuppressive treatment.

**Movement Disorders**

Anti–basal ganglia antibodies (ABGAs) have been described in association with poststreptococcal neurologic illnesses, but they show limited syndrome specificity, levels correlate poorly with disease course, and they do not appear to target the extracellular domain of neuronal proteins. However, patients with ABGAs can harbor other antibodies with pathogenic potential. In particular, NMDAR antibodies have been found in the serum and CSF of 50% of patients with a diagnosis of “encephalitis lethargica,” and dopamine-2–receptor antibodies have been reported in some patients with basal ganglia encephalitis, Sydenham chorea, and Tourette syndrome. In many of these patients, the movement disorder is the prominent feature, but there may be coexistent psychiatric symptoms, including obsessive–compulsive disorder, depression, and anxiety.

The movement disorder in patients with NMDAR antibodies frequently shows prominent orofacial involvement with additional complex bilateral movements of the limbs. The hyperkinetic movement phenomenon is heterogeneous and can include myoclonus, dystonia, chorea, and athetosis.

Interestingly, in the past 2 years several studies have identified NMDAR antibodies in patients with proven herpes simplex virus encephalitis (HSVE). The strongest association appears to be in children developing choreoathetosis and cognitive impairment weeks to months after proven HSVE, suggesting that NGSAbs can arise as a result of virally induced neuronal damage. Given the marked similarity of this presentation to many typical patients with NMDAR antibodies, and the observed response to immunotherapy, these NMDAR antibodies are likely to be pathogenic.

The spectrum of stiff-person–related disorders retain commonality in their subacute onset of otherwise unexplained spasms and stiffness and frequent association with high-titer GAD antibodies. The phenotypes can extend from axial-dominant stiff-person syndrome (SPS), or variant SPS with single limb involvement, to the progressive encephalomyelitis with rigidity and myoclonus (PERM) subtype with prominent encephalopathy and brainstem features. Some studies suggest that the variable degree of autonomic involvement, seizures, cerebellar ataxia, and cognitive impairment allows subcategorization of these disorders (see Fig 2B). In addition to these SPSs, the phenotype spread of GAD-antibody–associated syndromes now includes LE and some epilepsies (Fig 2B).

Antibodies to GABA AR-associated protein and gephyrin, both intracellular proteins, in some SPS patients are unlikely to represent in vivo targets of pathogenic antibodies. By contrast, the recent discovery of glycine-alpha1–receptor antibodies in PERM and a few cases with SPS, the association of dipeptidyl peptidase IV–related protein antibodies in 3 patients with a
Distinctive form of SPS, and the recognition that some patients with GABA<sub>4</sub>R-antibody and AMPAR-antibody LE also harbor GAD antibodies, suggest that potentially pathogenic NGSAbs may also be present in GAD-antibody-positive patients. Moreover, although classical SPS often responds adequately to benzodiazepines, antibodies to surface epitopes of glycine receptors are now found in a range of PERM and related syndromes, with excellent and preferential responses to immunotherapies. It is possible that NGSAbs against other proteins involved in inhibitory neurotransmission are awaiting discovery in several patients with GAD-antibody-associated disorders.

Finally, movement disorders (see Fig 2A) are also now recognized within the phenotypes of VGKC-complex antibody–associated disorders with reports of ataxia, parkinsonism, and chorea, and often coexist with cognitive impairment and seizures.

**Demyelinating Disease**

Neuromyelitis optica (NMO) is a disorder characterized by attacks of longitudinally extensive transverse myelitis (LETM) and optic neuritis. NMO was formerly classified as an aggressive variant of multiple sclerosis (MS), but is now known to fall within the spectrum of NGSAbs-associated CNS disorders and may respond adversely to medications commonly used for treatment of MS. Unlike antibody disorders targeting neuronal cell-surface antigens, the pathogenic antibody in about 80% of NMO patients targets the AQP4 water channel on astrocytes. Here again, the recognition of the AQP4 antibody has led to identification of different presentations, such as early intractable vomiting, fulminant parenchymal cerebral lesions, white matter lesions on brain MRI that can look similar to those seen in MS, and non–longitudinally extensive myelitis. By extension, the identification of the AQP4 antibody has led to the related syndrome being labeled under the umbrella term of NMO spectrum disorder (NMOSD), which encompasses all associated phenotypes, including isolated LETM or optic neuritis, and has enabled earlier diagnosis and treatment after the first NMO attack.

Importantly, pain is an increasingly recognized, disabling, and treatment-refractory feature of NMO. Neuropathic-type pain has also been associated with VGKC-complex antibodies, either in isolation or as part of neuromyotonia or Morvan syndrome. It is often immunotherapy-responsive, and there is an association with CASPR2 antibodies.

As in all the diseases discussed here, some patients with typical symptoms of NMO do not have the recognized antibody. Although this may be due to technical limitations, the existence of other antibodies is likely in some of these currently seronegative patients. In NMOSD, for instance, a significant number of AQP4-antibody–negative patients have antibodies against myelin oligodendrocyte glycoprotein (MOG), which may herald a less aggressive prognosis. Most recently, patients with NMDAR antibodies have been described with marked demyelinating changes on imaging and clinical features overlapping with NMO and MS. Like AQP4 and MOG, NMDARs are also expressed on glia.

**Current and Novel Assays Using Serum- and CSF-Based Diagnostics and Related Insights into Disease Biology**

**Antibody Testing: Native, Fixed, and Solubilized Antigens**

Classical paraneoplastic antibodies bind intracellular antigens that are exposed on paraformaldehyde-fixed rodent brain sections (see Fig 1E) and also after denaturation on Western blots. By contrast, although NGSAbs can often be detected on brain sections, they do not usually bind well to denatured antigens. The technique most likely to detect potentially pathogenic antibodies is the binding of serum or CSF immunoglobulin (Ig) G to live cells that express the native antigen on their surface (Cell-based assays (CBAs); see Fig 1A–C). Absence of binding to cells that express another antigen helps to demonstrate antibody specificity.

CBAs employing live mammalian cells have the advantage of exposing the patients’ antibodies only to the extracellular domains of native antigens. Fixed or permeabilized CBAs, however, may detect nonpathogenic antibodies to intracellular and fixation-exposed epitopes. Some groups prefer a combination of these CBA techniques, but only partly based on the antigen specificity (for example compare Boronat et al to Lancaster et al), whereas others adhere to a single method for all antigens. In our view, the ideal would be for local diagnostic laboratories to have live neuronal cultures for fast detection of a range of potential NGSAbs and/or live CBAs for identifying the targets; but these live cell assays are time-consuming and costly. Currently, therefore, most diagnostic laboratories use commercial kits that provide fixed brain tissue and fixed antigen-expressing cells with the possible limitations discussed above.

The clinical relevance of NGSAbs against LGI1 and CASPR2 is widely accepted. Contactin-2 antibodies are less common and often coexist with LGI1 or CASPR2 antibodies (see Fig 1F). Antibodies that immunoprecipitate the VGKC complex from solubilized mammalian brain membranes, but do not show LGI1/CASPR2/contactin-2
reactivity or bind to the surface of hippocampal neurons, may be directed against epitopes that are intracellular in vivo (eg, Fig 1F) and therefore not be pathogenic. This is consistent with their appearance in patients with chronic epilepsies60 and a variety of conditions that are not immunotherapy-responsive, such as sporadic CJD, transient global amnesia, and MS.118–120 It is similarly of interest that VGKC-complex antibodies from children rarely show LGI1/CASPR2/contactin-2 reactivity.37–39 However, sera from some patients with VGKC-complex antibodies without LGI1/CASPR2/contactin-2 reactivity do bind hippocampal neurons and associate with immunotherapy-responsive syndromes (A. Vincent, unpublished observations); the identity of these target proteins is not yet known.

**CSF and Serum Antibody Levels at Onset and after Treatment: Relationships to Intrathecal Synthesis**

There has been some confusion regarding the relative roles of CSF and serum antibodies in these diseases. In all known NGSAbs syndromes, absolute concentrations of NGSAbs in the serum are consistently higher than in CSF at diagnosis.30,31,41,42,46,75 These high serum levels of NGSAbs are especially unsurprising in patients with systemic tumors, including ovarian teratomas and small-cell lung cancers, which express the antigenic target and are highly likely to trigger the peripheral antibody production.45,121 But they are also consistently seen in nonparaneoplastic patients. In the minority of patients reported with NGSAbs in CSF and not in serum at disease onset,122 the apparent absence of peripheral antibody would necessitate invoking a strikingly different mechanism of autoimmunization and may be a consequence of the assay methodology (see below).

Absolute serum IgG levels are usually around 400× higher than those in CSF.9 With a normal blood–brain barrier (BBB), therefore, the CSF to serum ratios of any circulating antibody would be 1:400, indicating that the specific antibody within the CSF is not being produced intrathecally. However, for NMDAR antibodies, the ratio is often much higher, from only 1:4 to 1:3,204 (median ≈ 1:15).46,75,123 and similar ratios of 1:10 to 1:200 and 1:14 to 1:320 are reported for VGKC-complex antibodies30,31 and AMPAR antibodies, respectively.41 This indicates that there is more antigen-specific antibody in the CSF than expected by natural diffusion.

A comparison of the antigen-specific antibody to the amount of total IgG in the 2 compartments [(CSF NGSAb)/(CSF total IgG)]/[(serum NGSAb)/(serum total IgG)]) indicates the "intrathecal synthesis" of the particular antibody. In the normal situation, it would be 1. Values >1 imply that clonal B cells producing antigen-specific IgG have traversed the BBB and expanded intrathecally to secrete the specific antibodies. Intrathecal synthesis is seen with most NGSAbs,45,46,75,123 but its extent varies considerably between different diseases. Whereas it is frequently high in patients with NMDAR,46,50 AMPAR,41 GABAgR,42 and glycine-receptor antibodies,124 it is often lower in patients with VGKC-complex/LGI1 antibodies.30,31 Conversely, when NGSAbs are detected in serum but not in CSF, which can be the case at the onset of disease (A. Vincent, unpublished observations), it may be that the NGSAbs have traversed the BBB and have bound directly to their target within the brain parenchyma,125 and that intrathecal synthesis will follow as the disease progresses. Alternatively, their absence in the CSF may imply a low chance of pathogenicity.

Some of the confusion regarding serum versus CSF antibody levels, however, arises from different ways of presenting the data; in some studies the absolute levels of serum and CSF NGSAbs have first been normalized to total IgG levels in serum or CSF (eg, Dalmau et al45), whereas in others absolute concentrations are presented (eg, Irani et al,46 Suh-Lailam et al123). In addition, other interstudy differences include the dilutions used to test serum and CSF (compare Lancaster et al42 to Boronat et al121), and differences between live and fixed CBAs (discussed above).121 In Oxford, use of relatively concentrated serum (usually 1:20) and 1:1 diluted CSF, and exposure to purely extracellular targets (live CBA) has not identified any positive CSFs with negative paired sera. Nevertheless, there may be rare situations where the antibody generation occurs purely within the CNS, and for this reason clinicians should consider sending both serum and CSF for diagnosis of NGSAb-related disorders when possible.

These considerations are of relevance to treatments. Serum antibodies are often vulnerable to standard acute immunosuppressive therapies, such as corticosteroids, intravenous immunoglobulins (IVIG), and particularly plasma exchange (PLEX). Access to CNS antibodies and plasma cells, however, may be difficult with many chemotherapeutic agents.126 Therefore, it is unsurprising that we and others have observed cases where CSF antibodies postimmunotherapy appear more closely to track the disease course (Irani, Gelfand, and Geschwind, unpublished).122 However, there are examples where serum antibodies best correlate with the clinical course (A. Vincent, unpublished observations). So, as with testing at diagnosis, it may be that both serum and CSF provide complementary paraclinical information to guide ongoing immunotherapy and, in some cases, assessing for relapse activity. Given intrathecal synthesis of NGSAbs in most of these conditions, it may be that CNS-directed B-cell or plasma-cell depletion will be most effective.
Nevertheless, the repeated observations that PLEX is clinically useful and tumor removal hastens recovery \cite{140,45,46,127-130} suggest that removal of a plasma factor—such as antibodies—and reduction in ongoing peripheral autoimmune-ameliorate the CNS disease.

"False-Negative" Autoantibodies, "False-Positive" Autoantibodies, and Autoantibodies with Unproven Clinical Relevance

As the antibody specificity is often the defining feature of a reported cohort, a major difficulty with interpretation of the results lies in the absence of an independent gold standard for any of these conditions. This is especially evident for NMO\textsubscript{SD}.\cite{131}

Given several recent independent reports of serum and/or CSF NMDAR antibodies in asymptomatic individual\textsuperscript{132} and patients with nonrelapsing HSVE,\textsuperscript{22} paroxysmal exercise-induced dyskinesias,\textsuperscript{133} CJD,\textsuperscript{134} myelitis,\textsuperscript{135} and \textit{Klebsiella pneumoniae} meningitis (A. Tebo, personal communication),\textsuperscript{123} and the detection of serum NMDAR or VGKC-complex antibodies in a few patients with CJD and other nonimmune disorders (M. Rossi et al, submitted),\textsuperscript{118,119} the specificity and clinical relevance of some neuronal antibodies is in question.

When the assay methodologies include specificity controls, such as absent binding of antigen-specific sera to other antigens, results in healthy or disease controls do not necessarily represent false positives. Rather, these observations suggest that low levels of autoantibodies can exist in patients without recognized antibody-associated syndromes (see Tables 1 and 2), and may represent secondary immunization after neuronal damage and either have no effect, or could alter the course of the disease. A recent study suggested a high, age-related rate of NGSAbs especially against NMDAR (10%) in disease and healthy controls. Also, around 1% of healthy controls had CASPR2 and MOG NGSAbs.\textsuperscript{136} Although these figures include IgA and IgM subclasses, and some titers are low, they do emphasize the need to exercise caution in the interpretation of the clinical relevance of a positive result.

At present, despite ongoing phenotype spread, diagnosis and treatment decisions for NGSAb-associated disorders must continue to be based on the relevance of such antibodies to the clinical syndrome, and clinicians need to strike a balance between appropriate early, aggressive treatment and exposing patients to unnecessary immunotherapies.

Treatments: Concepts and Syndrome-Specific Approaches

There are no published randomized-controlled clinical trials in NGSAb-associated CNS diseases. Available treatment evidence comes from case and cohort studies, which suggest that early and more aggressive immunotherapy improves outcomes.\textsuperscript{30,46,50,68,69,137} Therapeutic aims in NGSAb-associated conditions include symptomatic control of the acute episode, reduction of existing antibody levels, suppression of future antibody production, and timely withdrawal of potentially toxic medications. In addition, tumor removal should always be considered when relevant. Important questions to ask prior to planning treatment regimens include when and how disability is accrued, and what the natural history of the condition is. In addition, when addressing the question of worsening, relapsing, or persistent symptoms in a patient with an established NGSAb-related diagnosis, it is important to assess whether such symptomatology reflects ongoing CNS disease activity or is the consequence of prior antibody-induced injury. It is also important to provide symptomatic treatment for comorbid psychiatric symptoms, seizures, fatigue, sleep disturbances, and pain syndromes that can accompany these syndromes or the postencephalitic aftermath.

In conjunction with symptomatic management, the acute phase is usually managed with variable combinations of high-dose corticosteroids, IVIG, and PLEX. There is evidence for a more rapid return of function after early corticosteroids in VGKC-complex antibody-associated LE\textsuperscript{30} and FBDS.\textsuperscript{69} The efficacy of IVIG and PLEX in NGSAb-associated encephalitis is unproven, but supportive reports do exist, especially for PLEX.\textsuperscript{128-130} However, our open-label observational analysis suggests that the addition of IVIG, PLEX, or both to corticosteroids in 64 patients with VGKC-complex/LGI1 antibody–associated LE did not appear to alter outcomes at a median of 4 years of follow-up (see Fig 3D; data modified from Irani et al\textsuperscript{135}). More robust data for PLEX are available for the treatment of NMO.\textsuperscript{104,106,138-139} Nevertheless, despite limited evidence IVIG and PLEX continue to be popular options because they have a rapid onset of action and are relatively accessible, and there remains an intuitive belief that their mechanisms of action and their efficacy in similar diseases should translate to clinical benefit. As IgGs are replaced with a half-life of 21 days,\textsuperscript{140} PLEX typically only serves as a bridge while more definitive immunotherapies are commenced to reduce antibody production. The use of high doses and long durations of corticosteroids in many of these conditions make steroid-sparing options important especially in diseases whose natural histories show the potential for a chronic or relapsing–remitting course, such as NMO and NMDAR-antibody encephalitis.

Observational studies have shown that NMO relapses are significantly reduced by chronic immunotherapy.
with glucocorticoids,\textsuperscript{141} azathioprine,\textsuperscript{142} methotrexate,\textsuperscript{143} mycophenolate mofetil (MMF),\textsuperscript{144} rituximab,\textsuperscript{145–147} mitoxantrone,\textsuperscript{148,149} tocilizumab,\textsuperscript{150} and eculizimab.\textsuperscript{151} No head-to-head or placebo trial has been performed, but in single-arm analyses azathioprine does appear to associate with a higher annualized relapse rate than MMF or rituximab,\textsuperscript{152} and was also associated with a relatively high rate of lymphoma.\textsuperscript{142} In NMDAR-antibody encephalitis, there is some evidence that patients with limited or no improvement after first-line immunotherapies may show longer-term benefit from more aggressive regimens including addition of rituximab and/or cyclophosphamide.\textsuperscript{46,137} This is very different from the experience with VGKC-complex/LGI1–antibody encephalitis (see Fig 3D), where there has been little published use of second-line immunotherapy, as this is usually a monophasic illness that has traditionally been treated with steroids with or without addition of PLEX/IVIG.\textsuperscript{30,153,154}

However, the toxicity of prolonged steroid regimes in the elderly, unanswered questions about relative efficacy of steroids versus other immunosuppressive options, and a significant minority of patients with poor cognitive and functional outcomes despite acute immunosuppression\textsuperscript{155} mean more aggressive or targeted immunotherapies such as rituximab\textsuperscript{156} merit future study.

Conclusions

Over the past decade, there has been a marked increase in the number of NGSAb targets identified that associate with CNS diseases, and a rapid expansion in the clinical features and demographics seen in conjunction with each antibody. This phenotype spread has highlighted the relevance of NGSABs to neurologists with an interest in epilepsy, cognition and behavior, movement disorders, and demyelinating disease. This antibody awareness has also highlighted the increasing requirement to exercise clinical judgment in the context of an incongruent clinical–serological picture and has emphasized the importance of understanding assay methodologies and appreciating concepts surrounding rational immunotherapy administration. Vigilance for an underlying tumor is required in all these syndromes to varying degrees, but the distinction between cell-surface and intracellular antigenic targets may be more important than the presence of an underlying tumor in guiding prognosis of paraneoplastic syndromes.

Future studies will need to address the pathogenicity of the antibodies, which patients with serum/CSF antibodies develop disease, whether B cells or NGSAbs or both enter the CNS to initiate the disease, and whether antibody titers help guide immunotherapy escalation and withdrawal. Research should aim to identify the clinical epidemiology of positive test results in determining the best guidelines for screening NGSAbs and its cost-effectiveness in the neurology clinic, and to offer efficient methods for worldwide diagnosis.

Acknowledgment

S.R.I. was supported by Epilepsy Research UK (P1201), by the Fulbright UK-US commission and the MS society (962/12), and by the BMA Vera Down Grant. A.V. was supported by the Oxford Biomedical Centre and the National Institute for Health Research. J.M.G. was supported by the National Center for Advancing Translational Sciences of the NIH (award number KL2TR000143). The contents of this review are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.

All coauthors have seen and agree with the contents of the article, the International Committee of Medical Journal Editors requirements for authorship have been met, and each author believes that the article represents honest work.

Authorship

The authors have all made substantial contributions to conception and design, acquisition of data, analysis and interpretation of data, drafting the manuscript, or revising it critically for important intellectual content, and have given final approval of the version to be published.

Potential Conflicts of Interest

S.R.I.: coapplicant patent with Oxford University for VGKC complex antibodies licensed to Euroimmun; royalties, (licensee ISIS). J.M.G.: medical–legal consulting related to CNS inflammatory–demyelinating disease. A.V.: consultancy, Athena Diagnostics; employment, Oxford University; holds patent with Oxford University for VGKC complex antibodies licensed to Euroimmun; royalties, Euroimmun, Athena Diagnostics.

References

1. Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004;75:1135–1140.
2. McKeon A, Pittock SJ. Paraneoplastic encephalomyelopathies: pathology and mechanisms. Acta Neuropathol 2011;122:381–400.
3. Vincent A, Bien CG, Irani SR, Waters P. Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol 2011;10:759–772.
4. Leypoldt F, Wandinger KP. Paraneoplastic neurological syndromes. Clin Exp Immunol 2014;175:336–348.
5. Tanaka M, Tanaka K, Shinozawa K, et al. Cytotoxic T cells react with recombinant Yo protein from a patient with paraneoplastic
cerebellar degeneration and anti-Yo antibody. J Neurol Sci 1998; 161:88–90.

6. Vincent A, Lily O, Palace J. Pathogenic autoantibodies to neuronal proteins in neurological disorders. J Neuroimmunol 1999;100: 169–180.

7. Lancaster E, Dalmau J. Neuronal autoantigens—pathogenesis, associated disorders and antibody testing. Nat Rev Neurol 2012; 8:390–390.

8. Zuliani L, Graus F, Giometto B, et al. Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. J Neurol Neurosurg Psychiatry 2012;83:638–645.

9. Fukuta Y, Adesnik H, Iwanaga T, et al. Epilepsy-related ligand/receptor complex LGI1 and ADAM22 regulate synaptic transmission. Science 2006;313:1792–1795.

10. Irani SR, Vincent A. Autoimmune encephalitis—new awareness, challenging questions. Discov Med 2011;11:449–458.

11. Irani SR, Vincent A. The expanding spectrum of clinically-distinctive, immunotherapy-responsive autoimmune encephalopathies. Arq Neuropsiquiatr 2012;70:300–304.

12. Granerod J, Cousens S, Davies NW, et al. New estimates of incidence of encephalitis in England. Emerg Infect Dis 2013;19(9).

13. Asgari N, Lillevang ST, Skejoe HP, et al. A population-based study of neuremyelitis optica in Caucasians. Neurology 2011;76:1589–1595.

14. Saiz A, Blanco Y, Sabater L, et al. Spectrum of neurological syndromes associated with glumatic acid decarboxylase antibodies: diagnostic clues for this association. Brain 2008;131:2553–2563.

15. Malter MP, Helmstaedter C, Urbach H, et al. Antibodies to glumatic acid decarboxylase define a form of limbic encephalitis. Ann Neurol 2010;67:470–478.

16. Vincent A. Stiff, twitchy or wobbly: are GAD antibodies pathogenic? Brain 2008;131:2536–2537.

17. Boronat A, Sabater L, Saiz A, et al. GABA(B) receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology 2011;76:795–800.

18. McKeon A, Martinez-Hernandez E, Lancaster E, et al. Glycine receptor autoimmunity spectrum with stiff-man syndrome phenotype. JAMA Neurol 2013;70:44–50.

19. Chang T, Alexopoulos H, McMennamin M, et al. Neuronal surface and glumatic acid decarboxylase autoantibodies in nonparaneoplastic stiff person syndrome. JAMA Neurol 2013;70:1140–1149.

20. Irani SR, Pettingill P, Kleopa KA, et al. Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol 2012;72:241–255.

21. Turner MR, Irani SR, Leite MJ, et al. Progressive encephalomyelitis with rigidity and myoclonus: glycine and NMDA receptor antibodies. Neurology 2011;77:439–443.

22. Pruss H, Finke C, Holtje M, et al. N-methyl-D-aspartate receptor antibodies in herpes simplex encephalitis. Ann Neurol 2012;72:902–911.

23. Machado S, Pinto AN, Irani SR. What should you know about limbic encephalitis? Arq Neuropsiquiatr 2012;70:817–822.

24. Geschwind MD, Shu H, Haman A, et al. Rapidly progressive dementia. Ann Neurol 2008;64:97–108.

25. Granerod J, Ambrose HE, Davies NW, et al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis 2010;10:835–844.

26. Chitravas N, Jung RS, Kofakay DM, et al. Treataable neurological disorders misdiagnosed as Creutzfeldt-Jakob disease. Ann Neurol 2011;70:437–444.

27. Gable MS, Sheriff H, Dalmau J, et al. The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. Clin Infect Dis 2012;54:899–904.

28. Rosenbloom MH, Smith S, Akdal G, Geschwind MD. Immunologically mediated dementias. Curr Neurol Neurosci Rep 2009;9:359–367.

29. Buckley C, Oger J, Clover L, et al. Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol 2001;50:73–78.

30. Vincent A, Buckley C, Schott JM, et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004;127:701–712.

31. Thieben MJ, Lennon VA, Boeve BF, et al. Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology 2004;62:1177–1182.

32. Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glial inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neumomyotonia. Brain 2010;133:2734–2748.

33. Lai M, Huijbers MG, Lancaster E, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 2010;9:776–785.

34. Geschwind MD, Tan KM, Lennon VA, et al. Voltage-gated potassium channel autoimmunity mimicking Creutzfeldt-Jakob disease. Arch Neurol 2008;65:1341–1346.

35. Dharmja R, Renaud DL, Pittoc SJ, et al. Neuronal voltage-gated potassium channel complex autoimmunity in children. Pediatr Neurol 2011;44:275–281.

36. Haberlandt E, Bast T, EBner A, et al. Limbic encephalitis in children and adolescents. Arch Dis Child 2011;96:186–191.

37. Hacohen Y, Wright S, Waters P, et al. Paediatric autoimmune encephalopathies: clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens. J Neurol Neurosurg Psychiatry 2013;84:748–755.

38. Suleiman J, Brenner T, Gill D, et al. VGKC antibodies in pediatric encephalitis presenting with status epilepticus. Neurology 2011;76:1252–1255.

39. Suleiman J, Brilot F, Lang B, et al. Autoimmune epilepsy in children: case series and proposed guidelines for identification. Epilepsia 2013;54:1036–1045.

40. Jeffery OJ, Lennon VA, Pittoc SJ, et al. GABAB receptor autoantibody frequency in service serologic evaluation. Neurology 2013;81:882–887.

41. Lai M, Hughes EG, Peng X, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 2009;65:424–434.

42. Lancaster E, Lai M, Peng X, et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 2010;9:67–76.

43. Somers KJ, Lennon VA, Rundell JR, et al. Psychiatric manifestations of voltage-gated potassium-channel complex autoimmunity. J Neuropsychiatry Clin Neurosci 2011;23:425–433.

44. Tan KM, Lennon VA, Klein CJ, et al. Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology 2008;70:1883–1890.

45. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008;7:1091–1098.

46. Irani SR, Bera K, Waters P, et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical...
observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010;133:1655–1667.

47. Kayser MS, Titulaer MJ, Gresa-Arribas N, Dalmau J. Frequency and characteristics of isolated psychiatric episodes in anti-N-methyl-D-aspartate receptor encephalitis. JAMA Neurol 2013;70:1133–1139.

48. Zandi MS, Irani SR, Lang B, et al. Disease-related autoantibodies in first episode schizophrenia. J Neurol 2011;258:666–688.

49. Dalmau J, Tuzun E, Wu HY, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007;61:25–36.

50. Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011;10:63–74.

51. Florance NR, Davis RL, Lam C, et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol 2009;66:11–18.

52. Hammer C, Stepniak B, Schneider A, et al. Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity. Mol Psychiatry. 2013 Sep 3. doi: 10.1038/mp.2013.110. [Epub ahead of print]

53. Steiner J, Walter M, Glanz W, et al. Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encephalitis. JAMA Psychiatry 2013; 70:271–278.

54. Dale RC, Merheb V, Pillai S, et al. Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders. Brain 2012;135:3453–3468.

55. Graus F, Boronat A, Xifro X, et al. The expanding clinical profile of anti-AMPA receptor encephalitis. Neurology 2010;74:857–859.

56. Shorvon SD. The etiologic classification of epilepsy. Epilepsia 2011;52:1052–1057.

57. Majoie HJ, de Baets M, Renier W, et al. Antibodies to voltage-gated potassium and calcium channels in epilepsy. Epilepsy Res 2006;71:135–141.

58. McKnight K, Jiang Y, Hart Y, et al. Serum antibodies in epilepsy and seizure-associated disorders. Neurology 2005;65:1730–1736.

59. Peltola J, Kulmala P, Isojarvi J, et al. Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy. Neurol 2009;66:704–709.

60. Mohamed SS, Sinclair K, Pillai S, et al. Herpes simplex encephalitis relapse with chorea is associated with autoantibodies to N-Methyl-D-aspartate receptor or dopamine-2 receptor. Mov Disord 2014;29:90–96.

61. Hacohen Y, Deiva K, Pettingill P, et al. N-methyl-D-aspartate receptor antibodies in post-herpes simplex virus encephalitis neurological relapse. Mov Disord 2014;29:543–547.

62. Hacohen Y, Dlamini N, Hedderly T, et al. N-methyl-D-aspartate receptor antibody-associated movement disorder without encephalopathy. Dev Med Child Neurol 2014;56:190–193.

63. Foo J, Schonberg J, Ang A, et al. Anti-AMPA receptor encephalitis in children with atypical dystonia and tics: a prospective study. Neurology 2004;63:156–158.

64. Butler MH, Hayashi A, Ohkoshi N, et al. Autoimmunity to gephyrin and variants: clinical course, treatments, and outcomes. Arch Neurol 2011;68:224–230.

65. Radojičić M, Balabani S, Topalovski B, et al. Autoimmune encephalitis with anti-NMDA receptor antibodies in pediatric dyskinetic encephalitis lethargica. JAMA Neurol 2013;70:704–709.

66. Raju R, Rakocevic G, Chen Z, et al. Autoimmunity to GABAA-receptor-associated protein in stiff-person syndrome. Brain 2006;129:3270–3276.

67. Butler MH, Hayashi A, Ohkoshi N, et al. Autoimmunity to gephyrin in stiff-man syndrome. Neuron 2000;26:307–312.

68. Irani SR, Michell AW, Lang B, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 2011;69:892–900.

69. Irani SR, Stagg CJ, Schott JM, et al. Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain 2013;136:3151–3162.
89. Hutchinson M, Waters P, McHugh J, et al. Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody. Neurology 2008;71:1291–1292.

90. Mas N, Saiz A, Leite MI, et al. Antiglycine-receptor encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry 2011;82:1399–1401.

91. Stern WM, Howard R, Chalmers RM, et al. Glycine receptor antibody-mediated progressive encephalomyelitis with rigidity and myoclonus (PERM): a rare but treatable neurological syndrome. Pract Neurol 2014;14:123–127.

92. Ballint B, Jarius S, Nagel S, et al. Progressive encephalomyelitis with rigidity and myoclonus: a new variant with DPPX antibodies. Neurology 2014;82:1521–1528.

93. Becker EB, Zuliani L, Pettingill R, et al. Contactin-associated protein-2 antibodies in non-paraneoplastic cerebellar ataxia. J Neurol Neurosurg Psychiatry 2012;83:437–440.

94. Tofaris GK, Irani SR, Cheever BJ, et al. Immunotherapy-responsive chorea as the presenting feature of LGI1-antibody encephalitis. Neurology 2012;79:195–196.

95. Lennon VA, Kyzer TJ, Pittcock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005;202:473–477.

96. Roemer SF, Parisi JE, Lennon VA, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007;130:1194–1205.

97. Kim SH, Kim W, Li XF, et al. Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder? Mult Scler 2012; 18:1480–1483.

98. Kleiter I, Hellwig K, Berthele A, et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 2012;69:239–245.

99. Waters P, Vincent A. Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays. Int MS J 2008;15:99–105.

100. Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 2012;78:665–671; discussion 669.

101. Popescu BF, Lennon VA, Parisi JE, et al. Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology 2011;76:1229–1237.

102. Newey CR, Bernel RA. Fulminant cerebral demyelination in neuromyelitis optica. Neurology 2011;77:193.

103. Pittcock SJ, Lennon VA, Krecke K, et al. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006;63:390–396.

104. Wingerchuk DM. Neuromyelitis optica spectrum disorders. Continuum (Minneap Minn) 2010;16:105–121.

105. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6:805–815.

106. Sellner J, Boggild M, Clanet M, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 2010;17:1019–1032.

107. Klein CJ, Lennon VA, Aston PA, et al. Chronic pain as a manifestation of potassium channel-complex autoimmunity. Neurology 2012;79:1136–1144.

108. Kitley J, Woodhall M, Waters P, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 2012;79:1273–1277.

109. Rostasy K, Mader S, Hennes EM, et al. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica. Mult Scler 2013;19:1052–1059.

110. Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014;82:474–481.

111. Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 2014;71:276–283.
131. Jacob A, McKeon A, Nakashima I, et al. Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. J Neurol Neurosurg Psychiatry 2013;84:922–930.

132. Hansen HC, Klingbeil C, Dalmau J, et al. Persistent intrathecal antibody synthesis 15 years after recovering from anti-N-methyl-D-aspartate receptor encephalitis. JAMA Neurol 2013;70:117–119.

133. Labate A, Quattrone A, Dalmau J, Gambardella A. Anti-N-methyl-D-aspartate-glutamic-receptor encephalitis presenting as paroxysmal exercise-induced foot weakness. Mov Disord 2013;28:820–822.

134. Mackay A, Ahmad K, Stone J, et al. NMDA receptor autoantibodies in sporadic Creutzfeldt-Jakob disease. J Neurol 2012;259:1979–1981.

135. Outteryck O, Baille G, Hodel J, et al. Extensive myelitis associated with anti-NMDA receptor antibodies. BMC Neurol 2013;13:211.

136. Dahm L, Ott C, Steiner J, et al. Seroprevalence of autoantibodies against brain antigens in health and disease. Ann Neurol. 2014 May 23. doi: 10.1002/ana.24189. [Epub ahead of print]

137. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013;12:157–165.

138. Sato DK, Nakashima I, Takahashi T, et al. Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders. Neurology 2013;80:2210–2216.

139. Lim YM, Pyun SY, Kang BH, et al. Factors associated with the effectiveness of plasma exchange for the treatment of NMO-IgG-positive neuromyelitis optica spectrum disorders. Mult Sccler 2013;19:1216–1218.

140. Kaplan AA. Therapeutic plasma exchange: core curriculum 2008. Am J Kidney Dis 2008;52:1180–1196.

141. Watanabe S, Misu T, Miyazawa I, et al. Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Sccler 2007;13:968–974.

142. Costanzi C, Mattiello M, Lucchinetti CF, et al. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 2011;77:459–466.

143. Kitley J, Elsone L, George J, et al. Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. J Neurol Neurosurg Psychiatry 2013;84:918–921.

144. Jacob A, Mattiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 2009;66:1128–1133.

145. Cree BA, Lamb S, Morgan K, et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005;64:1270–1272.

146. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008;65:1443–1448.

147. Pellkofer HL, Krumbholz M, Berthele A, et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 2011;76:1310–1315.

148. Kim SH, Kim W, Park MS, et al. Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. Arch Neurol 2011;68:473–479.

149. Weinstock-Guttman B, Ramanathan M, Lincoff N, et al. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol 2006;63:957–963.

150. Araki M, Aramami T, Matsuoka T, et al. Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol 2013;23:827–831.

151. Pitttock SJ, Lennon VA, McKeon A, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 2013;12:554–562.

152. Mealy MA, Wingerchuk DM, Palace J, et al. Comparison of Relapse and Treatment Failure Rates Among Patients With Neuromyelitis Optica: Multicenter Study of Treatment Efficacy. JAMA Neurol 2014;71:324–330.

153. Wong SH, Saunders MD, Lamers AJ, et al. An effective immunotherapy regimen for VGKC antibody-positive limbic encephalitis. J Neurol Neurosurg Psychiatry 2010;81:1167–1169.

154. Jaben EA, Winters JG. Plasma exchange as a therapeutic option in patients with neurologic symptoms due to antibodies to voltage-gated potassium channels: a report of five cases and review of the literature. J Clin Apher 2012;27:267–273.

155. Frisch C, Malter MP, Elger CE, Helmstaedter C. Neuropsychological course of voltage-gated potassium channel and glutamic acid decarboxylase antibody related limbic encephalitis. Eur J Neurol 2013;20:1297–1304.

156. Irani SR, Geifland JM, Betcher BM, et al. Effect of rituximab in patients with leucine-rich, glioma-inactivated 1 antibody-associated encephalopathy. JAMA Neurol 2014 May 19. doi: 10.1001/jamaneurol.2014.463. [Epub ahead of print]

157. Vincent A, Irani SR. Caspr2 antibodies in patients with thymomas. J Thorac Oncol 2010;5:S277–S280.

158. Otsuka T, Leite MA, Lang B, et al. Glycine receptor antibodies are detected in progressive encephalomyelitis with rigidity and myoclonus (PERM) but not in saccadic oscillations. J Neurol 2012;259:1566–1573.

159. Pitttock SJ, Lennon VA. Aquaporin-4 autoantibodies in a paraneoplastic context. Arch Neurol 2008;65:629–632.

160. Kayser MS, Titulaer MJ, Gresa-Arribas N, Dalmau J. Frequency and characteristics of isolated psychiatric episodes in anti-N-methyl-D-aspartate receptor encephalitis. Eur J Neurol 2013;20:1297–1304.

161. Rubio-Agusti I, Dalmau J, Sevilla T, et al. Isolated hemidystonia associated with NMDA receptor antibodies. Mov Disord 2011;26:351–352.

162. Niehusmann P, Dalmau J, Rudlofski C, et al. Diagnostic value of N-methyl-D-aspartate receptor antibodies in women with new-onset epilepsy. Arch Neurol 2009;66:458–464.

163. Tuzun E, Kinay D, Hacohen Y, et al. Guillain-Barre-like syndrome associated with lung adenocarcinoma and CASPR2 antibodies. Muscle Nerve 2013;48:836–837.

164. Eikzoglou E, Tuzun E, Woodhall M, et al. Investigation of neuronal autoantibodies in two different focal epilepsy syndromes. Epilepsia 2014;55:414–422.

165. Magana SM, Mattiello M, Pitttock SJ, et al. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology 2009;72:712–717.

166. Hupke P, Rostasy K, Karenfort M, et al. Acute disseminated encephalomyelitis followed by recurrent or monophasic optic neuritis in pediatric patients. Mult Scler 2013;19:941–946.